Publicacións (59) Publicacións nas que participase algún/ha investigador/a

2002

  1. A randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection: The ADHOC trial

    HIV Medicine, Vol. 3, Núm. 4, pp. 229-238

  2. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine

    AIDS, Vol. 16, Núm. 17, pp. 2352-2354

  3. Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts

    Journal of Infectious Diseases, Vol. 186, Núm. 2, pp. 189-197

  4. Care of patients with chronic hepatitis C and HIV co-infection: Recommendations from the HIV-HCV International Panel

    AIDS, Vol. 16, Núm. 6, pp. 813-828

  5. Clinical impact of HTLV-1 infection in Spain: Implications for public health and mandatory screening [3]

    Journal of Acquired Immune Deficiency Syndromes

  6. Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors

    International Journal of Antimicrobial Agents, Vol. 20, Núm. 6, pp. 438-443

  7. Cómo crear talento: la influencia del liderazgo en el capital humano

    Capital humano: revista para la integración y desarrollo de los recursos humanos, Año 15, Núm. 157, pp. 26-30

  8. Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Madrid

    AIDS, Vol. 16, Núm. 13, pp. 1830-1832

  9. Diagnóstico y desarrollo de competencias

    Revista DYNA, Vol. 77, Núm. 8, pp. 10-12

  10. Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors

    AIDS Research and Human Retroviruses, Vol. 18, Núm. 18, pp. 1379-1388

  11. Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides

    AIDS, Vol. 16, Núm. 2, pp. 245-249

  12. Does an increase in nevirapine plasma levels cause complete virologic suppression in patients experiencing early virologic failure?

    HIV Clinical Trials, Vol. 3, Núm. 6, pp. 463-474

  13. Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia

    AIDS, Vol. 16, Núm. 15, pp. 2079-2081

  14. Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter

    HIV Clinical Trials, Vol. 3, Núm. 1, pp. 9-16

  15. Entes eclesiásticos y libertad religiosa en el ordenamiento jurídico español

    Il Diritto ecclesiastico, Vol. 113, Núm. 2, pp. 583-596

  16. Evaluation of the Abbott LCx quantitative assay for measurement of human immunodeficiency virus RNA in plasma

    Journal of Clinical Microbiology, Vol. 40, Núm. 4, pp. 1518-1521

  17. Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor

    AIDS, Vol. 16, Núm. 14, pp. 1959-1961

  18. Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999

    Sexually Transmitted Infections, Vol. 78, Núm. 4, pp. 255-260

  19. Genetic mechanisms of resistance to NRTI and NNRTI

    HIV Clinical Trials, Vol. 3, Núm. 3, pp. 237-248

  20. Genetic mechanisms of resistance to protease inhibitors and entry inhibitors

    HIV Clinical Trials, Vol. 3, Núm. 3, pp. 249-257